According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Mira Pharma's investigational drug SKNY-1 has demonstrated promising pharmacokinetic characteristics in preclinical studies.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This compound exhibits good bioavailability, meaning it can be effectively absorbed into the systemic circulation after oral administration. More importantly, research data reveal that SKNY-1 demonstrates strong exposure levels in its target organs—the brain and the liver. This high concentration distribution in critical tissues provides a significant pharmacological foundation for its potential efficacy against central nervous system or liver-related diseases. Based on its favorable pharmacokinetic profile, especially its prolonged duration of action in vivo, SKNY-1 shows promise for once-daily dosing. If this straightforward dosing regimen is confirmed in subsequent clinical development, it will significantly improve patient medication adherence, becoming a major competitive advantage for this drug. The positive preclinical data disclosed through SEC filings provide official endorsement for the progress of Mira Pharma’s R&D project and offer the latest scientific evidence for investors interested in the company’s future development.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Aspo unit ESL Shipping signs transport agreement with Stegra
Reuters•2026/09/14 06:04
Fram Skandinavien August NAV falls 15% to SEK 7 per share
Reuters•2026/09/14 06:03
Orexo says FDA accepts IND for OX640 anaphylaxis treatment candidate
Reuters•2026/09/14 06:03
Svolder net asset value slips to SEK 59 per share as of Sept. 11
Reuters•2026/09/14 06:03
Crypto prices
MoreBitcoin
BTC
$77,725.56
+0.56%
Ethereum
ETH
$2,522.27
+0.01%
Tether USDt
USDT
$0.9996
-0.02%
BNB
BNB
$724.9
-0.17%
XRP
XRP
$1.38
+1.03%
USDC
USDC
$0.9999
+0.00%
Solana
SOL
$101.49
-0.28%
TRON
TRX
$0.3389
-0.17%
Hyperliquid
HYPE
$79.86
+0.59%
Zcash
ZEC
$1,137.3
-0.92%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now